Polaryx Therapeutics, Inc. (PLYX)

NASDAQ: PLYX · Real-Time Price · USD

4.120

+1.710 (70.95%)

Feb 17, 2026, 11:48 AM EST - Market open

Polaryx Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-8.21	-30.36	-3.78
Stock-Based Compensation	4.76	2.4	3.24
Other Operating Activities	-	26	-
Change in Accounts Payable	0.21	-0.4	-0.05
Change in Other Net Operating Assets	-0.07	-0.22	0.42
Operating Cash Flow	-3.31	-2.57	-0.17
Short-Term Debt Issued	-	0.07	0.13
Total Debt Issued	-	0.07	0.13
Short-Term Debt Repaid	-	-0.19	-
Total Debt Repaid	-	-0.19	-
Net Debt Issued (Repaid)	-	-0.13	0.13
Issuance of Common Stock	6.48	7.32	-
Financing Cash Flow	6.33	7.19	0.13
Net Cash Flow	3.01	4.62	-0.05
Levered Free Cash Flow	-	0.99	-
Unlevered Free Cash Flow	-	0.99	-
Change in Working Capital	0.14	-0.62	0.37

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q